Abstract 309P
Background
It is important to consider that prolonged opioid use or opioid overuse for a patient who completed radiation therapy (RT) can have harmful effects. In 2018, pharmacists working with oncologists at outpatient clinics conducted an opioid de-escalation program for HNC patients who completed radiation therapy (RT) at the National Cancer Center Hospital East (NCCHE). The aim of this retrospective study was to evaluate the feasibility of a pharmacist-led opioid de-escalation (PLODE) program for HNC patients by comparing the outcomes of patients who participated in the PLODE program and those who did not.
Methods
This time-series analysis compared the outcomes of patients who participated in the PLODE program after CRT completion between June 2018 and February 2019 and those of patients who completed CRT between June 2017 and March 2018 and did not participate in the program. The PLODE program consisted of (1) number of opioid rescues, (2) patient’s complaints and (3) purpose of opioid use to patients based on the WHO Pain Ladder.
Results
Sixty-one patients completed CRT between June 2018 and February 2019. Of these 61 patients, 16 (26%) used opioids at the time of CRT completion and participated in the PLODE program. Ninety-three patients completed CRT between June 2017 and March 2018, and 32 patients (34%) used opioids at the time of CRT completion; these patients were evaluated as the control group. Patients who participated in the PLODE program discontinued opioids statistically earlier than those in the control group (median time to opioid discontinuation 11 days vs 24.5 days, HR 0.31, 95% CI 0.16-0.60, p < 0.001). Between the two groups, there were no differences in time to opioid use, maximum opioid dosing, incidence of grade 3 oral mucositis or time to oral mucositis occurrence. No patients in the PLODE group restarted opioid use after opioid discontinuation or escalated opioid dosing due to the worsening of pain.
Conclusions
The study showed the feasibility of a PLODE program for HNC patients who completed CRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract